# Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy

> **NCT00800943** · PHASE2 · UNKNOWN · sponsor: **Chronic Lymphocytic Leukemia Research Consortium** · enrollment: 31 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Alemtuzumab (Campath-1H)

## Key facts

- **NCT ID:** NCT00800943
- **Lead sponsor:** Chronic Lymphocytic Leukemia Research Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2008-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800943, "Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00800943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*